Search

Your search keyword '"Ferrell, P Brent"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Ferrell, P Brent" Remove constraint Author: "Ferrell, P Brent"
209 results on '"Ferrell, P Brent"'

Search Results

1. T cells specific for α-myosin drive immunotherapy-related myocarditis

2. In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy

4. Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository

5. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

7. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

11. Metabolic alterations mediated by STAT3 promotes drug persistence in CML

14. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML)

16. Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk

17. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

21. Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis

22. Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis

23. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis

24. Supplementary Table from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia

26. Supplementary Figure from Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia

28. Supplementary Table 1 from Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types

30. Data from Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types

31. Supplementary Figures from Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types

32. Supplementary Table 2 from Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types

36. Multiomic Profiling of Human Clonal Hematopoiesis Reveals Genotype and Cell-Specific Inflammatory Pathway Activation

37. Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic–Epigenetic Cross-Talk

38. Metabolic alterations mediated by STAT3 promotes drug persistence in CML

41. Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

42. Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia

44. Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase

46. The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib

47. Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation

Catalog

Books, media, physical & digital resources